Abstract: Compositions, devices, and methods for transdermal administration of olanzapine and uses thereof, e.g., to treat nausea and vomiting.

Abstract: Kits, compositions, devices, and methods for administration of olanzapine are provided. Uses thereof to treat nausea and vomiting are also provided.

Abstract: Transdermal drug delivery systems and methods of fabricating such systems are provided. The active pharmaceutical ingredient can be lenalidomide or other immunomodulatory agents. More particularly, the present invention is directed to improving the solubility of lenalidomide and other immunomodulatory imide compounds and improving the permeation of such compounds through the skin.

Abstract: Provided are compositions comprising a stable solution of an immune-mediated inflammatory disease (IMID) agent, such as an immunomodulatory imide drug (IMiD) including, but not limited to, lenalidomide (LLD). More particularly, embodiments relate to stable solutions of IMiDs for parenteral use. Methods of preparing stable solutions of IMiDs are also provided. In some embodiments, methods of treating inflammatory disorders and cancer(s) by parenteral use of stable IMiD solutions, and formulations thereof, are provided.

Abstract: Provided are systems and methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.

Abstract: Provided are methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.

Abstract: Provided are methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.

Abstract: A transdermal drug delivery system is provided that includes a drug-in-adhesive matrix layer and a backing layer. The matrix layer includes an active pharmaceutical ingredient, a cross-linked polyvinylpyrrolidone binder, a mesoporous silicon dioxide filler, and a pressure sensitive adhesive, while the backing layer forms an exterior facing-surface of the delivery system. The ratio of the mesoporous silicon dioxide filler to the cross-linked polyvinylpyrrolidone binder ranges from about 1:1 to about 1:8. As a result of the specific components of the matrix layer and the amounts in which they are utilized, the resulting delivery system, which can include a homogeneous dispersion of the active pharmaceutical ingredient in the formulation, is capable of delivering the active pharmaceutical ingredient over a period of up to about 7 days in a generally constant and controlled fashion. Further, the only layer that contemplates the use of an adhesive component is the drug-in-adhesive matrix layer.

Abstract: A transdermal drug delivery system is provided that includes a drug-in-adhesive matrix layer and a backing layer. The matrix layer includes an active pharmaceutical ingredient, a cross-linked polyvinylpyrrolidone binder, a mesoporous silicon dioxide filler, and a pressure sensitive adhesive, while the backing layer forms an exterior facing-surface of the delivery system. The ratio of the mesoporous silicon dioxide filler to the cross-linked polyvinylpyrrolidone binder ranges from about 1:1 to about 1:8. As a result of the specific components of the matrix layer and the amounts in which they are utilized, the resulting delivery system, which can include a homogeneous dispersion of the active pharmaceutical ingredient in the formulation, is capable of delivering the active pharmaceutical ingredient over a period of up to about 7 days in a generally constant and controlled fashion. Further, the only layer that contemplates the use of an adhesive component is the drug-in-adhesive matrix layer.

Abstract: A transdermal formulation and method of treatment includes providing an active pharmaceutical ingredient, a poly-isobutylene or silicone PSA, optionally, an oil, a crosslinked polyvinylpyrrolidone, and optionally, silicon dioxide, wherein said formulation is prepared on a backing in a three layer transdermal delivery system formulated to provide transdermal delivery and therapeutic levels for up to seven days and optionally with an overlay system required to show bioequivalence.